A new publication involving anamorelin appeared in the journal Internal Medicine (Tokyo, Japan) on July 25, 2026. The paper is titled "Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia." Anamorelin remains classified as an unapproved research compound. The publication is indexed under PubMed ID 42528246. This report notes only that the study has been published, without detailing its findings or conclusions. Anamorelin has been studied in the context of cancer cachexia, a condition involving reduced food intake and weight loss in cancer patients. The listed journal and date represent the recorded facts of this publication event. No outcome data, efficacy claims, or safety conclusions are included in this brief beyond the title and publication details provided. Readers interested in the broader context of anamorelin research can consult the compound overview for additional background information.
New Publication on Anamorelin and Cachexia Biomarkers
See the full anamorelin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42528246/